Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
about
Nonlinear partial differential equations and applications: The mechanism of topoisomerase I poisoning by a camptothecin analogSequence-specific targeting of IGF-I and IGF-IR genes by camptothecinsDNA fingerprinting of the NCI-60 cell line panel.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.Structure-based design, synthesis, and biological studies of new anticancer norindenoisoquinoline topoisomerase I inhibitorsThe indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.Evaluation of two models for human topoisomerase I interaction with dsDNA and camptothecin derivativesReduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.Decrease in topoisomerase I is responsible for activation-induced cytidine deaminase (AID)-dependent somatic hypermutation.Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomasMutations in topoisomerase I as a self-resistance mechanism coevolved with the production of the anticancer alkaloid camptothecin in plantsCharacterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutationsThe perinucleolar compartment is directly associated with DNA.Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.Development of trastuzumab-resistant human gastric carcinoma cell lines and mechanisms of drug resistance.FL118 induces p53-dependent senescence in colorectal cancer cells by promoting degradation of MdmX.Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.Protein concerted motions in the DNA-human topoisomerase I complex.Role of the linker domain and the 203-214 N-terminal residues in the human topoisomerase I DNA complex dynamics.DNA-based sensor for real-time measurement of the enzymatic activity of human topoisomerase ITopoisomerase I (Top1): a major target of FL118 for its antitumor efficacy or mainly involved in its side effects of hematopoietic toxicity?Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?Characterization of Camptothecin-induced Genomic Changes in the Camptothecin-resistant T-ALL-derived Cell Line CPT-K5.
P2860
Q27639935-259B279B-F151-41EE-8289-4BCC1F51F571Q33533698-39B9FE62-44CC-48DB-9E4B-FED1F55B4E19Q33608214-11F8D34F-8B56-4C61-884E-BDD9BC5C52B6Q33662415-84D13B5A-A05E-41BD-992C-9FDB5905F048Q33725863-FB8CB411-CDAA-4866-A548-30591EC9AA3EQ33925798-BD15BCF3-90F9-4994-980C-9FE0A8026140Q34017703-BA15074F-FE91-4A21-A0D1-115011A71B74Q34385596-291A36BC-803C-4093-9BCD-671C0211C3C8Q35161740-5382DB51-640E-486A-B2E8-189EF754A8AFQ35585876-873FFFBB-7A5C-4F6E-A772-231BA9FB9A21Q35652389-2FD3E804-E665-400A-BE9E-172A6025A8D7Q36627605-16B09A95-201B-4B87-AD3C-A79169D24854Q36749303-AEB604B7-64A0-435E-9DE8-F6BBA59B46ADQ37094171-A761AB12-C228-4652-8009-507B813E560EQ37197502-1045E917-1D03-41C6-9BE2-1E53F0FD0A12Q37651817-1915CF4E-E69E-47C5-AD79-1AB8568E65B7Q37652515-6B9ABA2A-FEF0-459B-B3DC-445F1757DC72Q37697431-6F9F01E0-C720-4231-A950-3AE9C40A2F3FQ38860383-B04AD6B5-F4F9-4E22-AD56-4BA260B4323FQ38928235-4F379445-50CE-437A-B931-C6BAD85342BDQ39439111-D4EB09AD-CBF6-4CF2-8236-730D5EB184C9Q39733795-7562A5E9-1E11-4F3E-A665-D259EBA38CF3Q40308617-78C49404-7198-4414-8FDB-857B37F506E9Q41550168-2B52F514-F6AF-4FE1-BCBD-90CF7DE7501DQ42318574-506F7B4D-509A-4C66-8326-5DAEE94AA406Q47220295-82C85556-F07B-4E1E-9151-A63F396B7073Q52678451-D3A85DF5-8720-4A67-8CBB-B11785761731
P2860
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Characterization of a novel to ...... man prostate cancer cell line.
@en
type
label
Characterization of a novel to ...... man prostate cancer cell line.
@en
prefLabel
Characterization of a novel to ...... man prostate cancer cell line.
@en
P2093
P1433
P1476
Characterization of a novel to ...... uman prostate cancer cell line
@en
P2093
Chatterjee D
Kohlhagen G
Pantazis P
Pourquier P
Takebayashi Y
P304
P407
P577
2001-03-01T00:00:00Z